The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
Abstract
BACKGROUND.: Growth factor overexpression, including epidermal growth factor receptor (EGFR) expression, is common in hepatocellular cancers. Erlotinib is a receptor tyrosine kinase inhibitor with specificity for EGFR. The primary objective of this study was to determine the proportion of hepatocellular carcinoma (HCC) patients treated with erlotinib who were alive and progression‐free (PFS) at 16 weeks of continuous treatment. METHODS.: Patients with unresectable HCC, no prior systemic therapy, performance status (PS) of 0, 1, or 2, and Childs‐Pugh (CP) cirrhosis A or B received oral erlotinib 150 mg daily for 28‐day cycles. Tumor response was assessed every 2 cycles by using Response Evaluation Criteria in Solid Tumors (RECIST; National Cancer Institute Cancer Therapy Evaluation Program, Bethesda, Md) criteria. Patients accrued to either “low” or “high” EGFR expression cohorts; each cohort had stopping rules applied when there was a lack of efficacy. RESULTS.: Forty HCC patients were enrolled. Median age was 64 years (range, 33–83 years), sex distribution was 32 males and 8 females, performance scores were 40% PS 0, 55% PS 1, Childs‐Pugh distribution was 75% A and 20% B. There were no complete or partial responses; however, 17 of 40 patients achieved stable disease at 16 weeks of continuous therapy. The PFS at 16 weeks was 43%, and the median overall survival (OS) was 43 weeks (10.75 months). No patients required dose reductions of erlotinib. No correlation between EGFR expression and outcome was found. CONCLUSIONS.: Results of this study indicated that single‐agent erlotinib is well tolerated and has modest disease‐control benefit in HCC, manifested as modestly prolonged PFS and OS when compared with historical controls. Cancer 2007. Published 2007 by the American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Parkin, D. M., Pisani, P., & Ferlay, J. (1999) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.1.33 · Cited by 3,376
Spiess, P. E., Lee, A. K., Leibovici, D., Wang, X., Do, K., & Pisters, L. L. (2006) · Cancer · doi:10.1002/cncr.21979 · Cited by 1,930
Self-citationHerbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Abou-Alfa, G. K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., De Greve, J., Douillard, J.-Y., Lathia, C., Schwartz, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195
Derynck, R., Goeddel, D. V., Ullrich, A., Gutterman, J. U., Williams, R. D., Bringman, T. S., & Berger, W. H. (1987) · PubMed · Cited by 898
Yeo, W., Mok, T. S., Zee, B., Leung, T. W. T., Lai, P. B. S., Lau, W. Y., Koh, J., Mo, F. K. F., Yu, S. C. H., Chan, A. T., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji315 · Cited by 590
Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T., Picus, J., & Erlichman, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.696 · Cited by 462
FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets
Cohen, M. H., Johnson, J. R., Chen, Y.-F., Sridhara, R., & Pazdur, R. (2005) · The Oncologist · doi:10.1634/theoncologist.10-7-461 · Cited by 445
Hepatic Resection for Hepatocellular Carcinoma An Audit of 343 Patients
Lai, E. C. S., Fan, S.-T., Lo, C.-M., Chu, K.-M., Liu, C.-L., & Wong, J. (1995) · Annals of Surgery · doi:10.1097/00000658-199503000-00012 · Cited by 400
Zhu, A. X., Blaszkowsky, L. S., Ryan, D. P., Clark, J. W., Muzikansky, A., Horgan, K., Sheehan, S., Hale, K. E., Enzinger, P. C., Bhargava, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9130 · Cited by 388
Steatosis: Co-factor in Other Liver Diseases *
Powell, E. E., Jonsson, J. R., & Clouston, A. D. (2005) · Hepatology · doi:10.1002/hep.20750 · Cited by 374
Hepatic resection for hepatocellular carcinoma
Suenaga, M., Nakao, A., Harada, A., Nonami, T., Okada, Y., Sugiura, H., Uehara, S., & Takagi, H. (1992) · World Journal of Surgery · doi:10.1007/bf02067120 · Cited by 359
Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?
Nair, S., Mason, A., Eason, J., Loss, G., & Perrillo, R. P. (2002) · Hepatology · doi:10.1053/jhep.2002.33713 · Cited by 348
Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma
Ito, Y., Takeda, T., Sakon, M., Tsujimoto, M., Higashiyama, S., Noda, K., Miyoshi, E., Monden, M., & Matsuura, N. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1580 · Cited by 321
Regulation of Liver Growth: Protooncogenes and Transforming Growth Factors
Fausto, N., & Mead, J. E. (1990) · Pathology Reviews • 1990 · doi:10.1007/978-1-4612-0485-5_1 · Cited by 309
[New guidelines to evaluate the response to treatment in solid tumors].
Duffaud, F., & Therasse, P. (2000) · PubMed · Cited by 174
Neaud, V, Faouzi, S., Guirouilh, J., Le Bail, B., Balabaud, C., Bioulac-Sage, P., & Rosenbaum, J. (1997) · Hepatology · doi:10.1002/hep.510260612 · Cited by 167
Randomized Controlled Trial of Tamoxifen in Advanced Hepatocellular Carcinoma
Barbare, J., Bouché, O., Bonnetain, F., Raoul, J., Rougier, P. R., Abergel, A., Boige, V., Denis, B., Blanchi, A., Pariente, A. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.470 · Cited by 134
Neo, S. Y., Leow, C. K., Vega, V. B., Long, P. M., Islam, A. F. M., Lai, P. B. S., Liu, E. T., & Ren, E. C. (2004) · Hepatology · doi:10.1002/hep.20105 · Cited by 111
Diverse expression of ErbB receptor proteins during rat liver development and regeneration
Carver, R. S., Stevenson, M. C., Scheving, L. A., & Russell, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37060 · Cited by 111
Thalidomide in the treatment of patients with hepatocellular carcinoma: A Phase II trial
Patt, Y. Z., Hassan, M. M., Lozano, R. D., Nooka, A. K., Schnirer, I. I., Zeldis, J. B., Abbruzzese, J. L., & Brown, T. D. (2005) · Cancer · doi:10.1002/cncr.20821 · Cited by 96
Self-citationHöchster, H. S., Haller, D. G., de Gramont, A., Berlin, J. D., Philip, P. A., Moore, M. J., & Ajani, J. A. (2006) · Cancer · doi:10.1002/cncr.22036 · Cited by 87
Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma
Lee, J., Park, J. O., Kim, W. S., Park, S. H., Park, K. W., Choi, M. S., Lee, J. H., Koh, K. C., Paik, S. W., Yoo, B. C., et al. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0837-7 · Cited by 83
Brief Communication: A New Combination in the Treatment of Advanced Pancreatic Cancer
Moore, M. J. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.07.017 · Cited by 64
Boige, V., Taïeb, J., Hebbar, M., Malka, D., de Baère, T., Hannoun, L., Magherini, E., Mignard, D., Poynard, T., & Ducreux, M. P. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.09.034 · Cited by 64
Yang, T.-S., Wang, C., Hsieh, R., Chen, J. S., & Fung, M. C. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf303 · Cited by 58
Eckel, F., von Delius, S., Mayr, M. F., Dobritz, M., Fend, F., Hosius, C., Schleyer, E., Schulte‐Frohlinde, E., Schmid, R. M., & Lersch, C. (2005) · Oncology · doi:10.1159/000089990 · Cited by 56
Mok, T. S. K., Leung, T. W. T., Lee, S., Chao, Y., Chan, A. T. �., Huang, A. T., Lui, M.-C., Yeo, W., Chak, K., Johnston, A. L., et al. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050982 · Cited by 47
Effects of TGF‐βs in the Liver: Cell Proliferation and Fibrogenesis
Fausto, N., Mead, J. E., Gruppuso, P. A., Castilla, A., & Jakowlew, S. B. (2007) · Novartis Foundation symposium · doi:10.1002/9780470514061.ch11 · Cited by 42
Overview of the Current Status of Human Epidermal Growth Factor Receptor Inhibitors in Lung Cancer
Herbst, R. S., & Sandler, A. B. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.s.009 · Cited by 40
Posey, J. A., Johnson, P., Mok, T. S. K., Hirmand, M., Dahlberg, S., Kwei, L., & Leung, T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.4035 · Cited by 31
Protooncogenes and growth factors associated with normal and abnormal liver growth
Fausto, N. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01297034 · Cited by 28
Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer
Byrne, B. J., & Garst, J. L. (2005) · Current Oncology Reports · doi:10.1007/s11912-005-0045-6 · Cited by 20
Cited by
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
Bruix, J., Reig, M., & Sherman, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.041 · Cited by 1,694
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
Whittaker, S., Marais, R., & Zhu, A. X. (2010) · Oncogene · doi:10.1038/onc.2010.236 · Cited by 825
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Llovet, J. M., Villanueva, A., Lachenmayer, A., & Finn, R. S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.103 · Cited by 621
Zhu, A. X., Rosmorduc, O., Evans, T. R. J., Ross, P. J., Santoro, A., Carrilho, F. J., Bruix, J., Qin, S., Thuluvath, P. J., Llovet, J. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.7746 · Cited by 576
Metadata
- Authors
- Thomas, M. B., Chadha, R., Glover, K., Wang, X., Morris, J., Brown, T., Rashid, A., Dancey, J., & Abbruzzese, J. L.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-08-20
- Volume
- 110
- Issue
- 5
- Pages
- 1059-1067
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2106036268
- Cited by
- 306
- References
- 40
- FWCI
- 22.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.